Clinical Research Directory

Key Inclusion Criteria: * 18 years old or older * Willing to sign an informed consent form * Willing to refrain from sexual intercourse or must use a contraceptive method that is highly effective for 90 days after the last dose of TGD001 * Symptomatic acute TMA episode * Accessible to follow-up Key Exclusion Criteria: * Diagnosis other than TMA, which could account for the findings of thrombocytopenia and hemolytic anemia * Diagnosis of Shiga-toxin induced HUS * Known bone marrow/graft failure * Diagnosis of ongoing severe, uncontrolled Graft versus Host Disease * Received therapeutic plasma exchange (PEX) within 7 days prior to screening * Use of an anticoagulant and/or thrombolytics * Active internal bleeding * Any major bleeding episode within the past 30 days, or diagnosis of chronic bleeding conditions * Known gastrointestinal ulcer * Severe, uncontrolled hypertension, renal impairment requiring dialysis, or liver impairment, or active infection indicated by sepsis * Life expectancy less than 3 months independent of TMA disorder * Pregnant or breastfeeding